Key Takeaways
- • IP Group said on Friday, October 16, 2026 that portfolio company Microbiotica Ltd. has raised £36 million ($48 million) to develop a treatment for ulcerative colitis, a chronic inflammatory bowel disease.
- • The financing is a portfolio-level liquidity and value event for IP Group, a University-spinout-focused investor, as it shows continued follow-on capital for a company in its life sciences holdings.
- • The primary source reports the raise but does not disclose the investor syndicate, valuation, or clinical stage, limiting assessment of the round's terms.
Summary
IP Group announced on Friday that its portfolio company Microbiotica Ltd. has raised £36 million ($48 million) to develop a treatment for ulcerative colitis, a chronic inflammatory bowel disease, according to a report by Law360. The announcement was made by IP Group, the London-listed investor that backs university spinouts and early-stage technology companies.
Microbiotica is focused on microbiome-based therapeutics, and the new capital is intended to advance its development program for ulcerative colitis, a condition that causes chronic inflammation of the colon and for which patients often rely on long-term immunosuppressive or biologic therapies. The source article does not detail the stage of the program, the composition of the investor group, or the post-money valuation of the company.
For institutional allocators tracking life sciences portfolios, the round signals continued access to follow-on capital for a microbiome company in the inflammatory bowel disease space. Further details on the financing terms and clinical timeline were not available in the primary source.
Microbiotica is focused on microbiome-based therapeutics, and the new capital is intended to advance its development program for ulcerative colitis, a condition that causes chronic inflammation of the colon and for which patients often rely on long-term immunosuppressive or biologic therapies. The source article does not detail the stage of the program, the composition of the investor group, or the post-money valuation of the company.
For institutional allocators tracking life sciences portfolios, the round signals continued access to follow-on capital for a microbiome company in the inflammatory bowel disease space. Further details on the financing terms and clinical timeline were not available in the primary source.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.